Table 1 Clinicopathological variables in the patients entered into this study
Characteristic | No. of patients (%) |
|---|---|
Total | 103 (100) |
Age (years) | |
≤50 | 31 (30) |
>50 | 72 (70) |
Invasive tumours | |
Lymph node status | |
Negative | 37 (41) |
Positive | 53 (59) |
Not assessed | 13 |
Invasive tumour grade | |
Grade I | 16 (16) |
Grade II | 51 (49) |
Grade III | 36 (35) |
Invasive tumour size (cm) | |
≤2 cm | 53 (52) |
>2 cm | 48 (48) |
Multifocal | 2 |
Lymphovascular invasion | |
Present | 50 (50) |
Absent | 50 (50) |
Not assessed | 3 |
NPI | |
GPG < 3.4 | 34 (39) |
MPG 3.4–5.4 | 37 (42) |
PPG > 5.4 | 17 (19) |
Not possible to calculate | 15 |
ER (quick-score) | |
Positive (4–8) | 63 (64) |
Negative (0–3) | 36 (36) |
Not assessed | 4 |
HER-2 IHC | |
Negative (0/1+) | 87 (84) |
Positive (2+/3+) | 16 (16) |
Ki67 IHC | |
Low proliferation, <10% | 51 (50) |
High proliferation, ≥10% | 52 (50) |
Ductal carcinoma in situ | |
VNPC | |
Grade I | 23 (24) |
Grade II | 36 (37) |
Grade III | 38 (39) |
Not assessed | 6 |
ER (quick-score) | |
Positive (4–8) | 61 (64) |
Negative (0–3) | 35 (36) |
Not assessed | 7 |
HER-2 IHC | |
Negative (0/1+) | 77 (80) |
Positive (2+/3+) | 19 (20) |
Not assessed | 7 |
Ki67 IHC | |
Low proliferation, <10% | 61 (59) |
High proliferation, ≥10% | 42 (41) |